In intensive discussions, participants received valuable feedback, concrete recommendations for action, and crucial information on topics such as clinical development, regulation, financing, law, intellectual property, and market access. The open exchange and the "expert review" were particularly appreciated, as they highlighted strengths while also addressing critical questions.
A heartfelt thank you goes to our experts who contributed their time, knowledge and experience:
Ghazaleh G. (Gouya Insights – Clinical Development)
Steve Jeitler (E+H Rechtsanwälte GmbH)
Markus Habernig (BDO Austria GmbH)
Michael Kerschbaumer (SFG)
Lydia Morawetz (PRSG Pharmaceutical and Regulatory Services GmbH)
Andreas Pföstl (Schwarz & Partner Patent Attorneys OG)
Martin Schmid (en.co.tec Schmid KG)
Michael Schmidbauer (Inspiralia GmbH)
We would also like to thank the dedicated participants who presented their projects and openly received feedback.
The feedback from one participant particularly aptly summarizes the added value of the format:
“I come from an academic background, from science, so it was very valuable for me to receive concrete input on developing a new product and on the expectations of investors and regulatory authorities. The ‘expert review’ made it clear to me how crucial reliable figures – for example, on cost and performance gains – as well as a clearly structured approach are. Now I am very much looking forward to the follow-ups and deepening the newly established contacts.”